Cancer epigenomics and beyond: Advancing the precision oncology paradigm

Research output: Contribution to journalReview articlepeer-review


How cancers are characterized and treated has evolved over the past few decades. Major advances in genomics tools and techniques have revealed interlinked regulatory pathways of cancers with unprecedented detail. Early discoveries led to success with rationally targeted small molecules and more recently with immunomodulatory agents, setting the stage for precision oncology. However, drug resistance to every agent has thus far proven intractable, sending us back to fill the gaps in our rudimentary knowledge of tumor biology. Epigenetics is emerging as a fundamental process in every hallmark of cancer. Large-scale interrogation of the cancer epigenome continues to reveal new mechanisms of astounding complexity. In this review, I present selected experimental and clinical examples that have shaped our understanding of cancer at the molecular level. Translation of our collective erudition into revolutionary diagnostic and treatment strategies will advance the precision oncology paradigm.

Original languageEnglish (US)
Pages (from-to)147-156
Number of pages10
JournalJournal of Immunotherapy and Precision Oncology
Issue number4
StatePublished - 2020


  • Cancer
  • Epigenomics
  • Epitranscriptomics
  • Genomics
  • Immune checkpoint inhibitors
  • Immuno-oncology
  • Molecular therapy
  • Noncoding RNA
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Cancer epigenomics and beyond: Advancing the precision oncology paradigm'. Together they form a unique fingerprint.

Cite this